Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.65+0.01 (+1.31%)
Close on Nov 12, 2026Market cap $255.73MP/E 3.0Yield –
Standard BioTools total assets
Total assets on the balance sheet at the end of each period.
Standard BioTools's total assets was $627.22M at Jun 30, 2026. For fiscal 2025 it was $567.75M, down 7.3% from the year before. Over ten years it grew 4.4% a year on average. The highest annual figure on record is $612.35M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.75M | -7.3% |
| FY2024 | Dec 31, 2024 | $612.35M | +89.5% |
| FY2023 | Dec 31, 2023 | $323.07M | -17.2% |
| FY2022 | Dec 31, 2022 | $390.31M | +41.8% |
| FY2021 | Dec 31, 2021 | $275.21M | -15.3% |
| FY2020 | Dec 31, 2020 | $324.76M | +22.6% |
| FY2019 | Dec 31, 2019 | $264.81M | -12.8% |
| FY2018 | Dec 31, 2018 | $303.65M | +5.7% |
| FY2017 | Dec 31, 2017 | $287.35M | -6.2% |
| FY2016 | Dec 31, 2016 | $306.40M | -17.2% |
| FY2015 | Dec 31, 2015 | $370.05M | -9.2% |
| FY2014 | Dec 31, 2014 | $407.56M | +248.6% |
| FY2013 | Dec 31, 2013 | $116.92M | +2.8% |
| FY2012 | Dec 31, 2012 | $113.73M | +43.4% |
| FY2011 | Dec 31, 2011 | $79.33M | +219.9% |
| FY2010 | Dec 31, 2010 | $24.80M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $627.22M | +12.6% |
| Q1 FY2026 | Mar 31, 2026 | $639.11M | +10.3% |
| Q4 FY2025 | Dec 31, 2025 | $567.75M | -7.3% |
| Q3 FY2025 | Sep 30, 2025 | $539.64M | -20.8% |
| Q2 FY2025 | Jun 30, 2025 | $556.97M | -21.4% |
| Q1 FY2025 | Mar 31, 2025 | $579.60M | -25.5% |
| Q4 FY2024 | Dec 31, 2024 | $612.35M | +89.5% |
| Q3 FY2024 | Sep 30, 2024 | $681.54M | +100.9% |
| Q2 FY2024 | Jun 30, 2024 | $708.73M | +99.2% |
| Q1 FY2024 | Mar 31, 2024 | $777.67M | +109.2% |
| Q4 FY2023 | Dec 31, 2023 | $323.07M | -17.2% |
| Q3 FY2023 | Sep 30, 2023 | $339.29M | -18.2% |
| Q2 FY2023 | Jun 30, 2023 | $355.83M | -19.3% |
| Q1 FY2023 | Mar 31, 2023 | $371.65M | +36.7% |
| Q4 FY2022 | Dec 31, 2022 | $390.31M | +41.8% |
| Q3 FY2022 | Sep 30, 2022 | $414.92M | +47.0% |
| Q2 FY2022 | Jun 30, 2022 | $441.12M | +52.5% |
| Q1 FY2022 | Mar 31, 2022 | $271.94M | -10.9% |
| Q4 FY2021 | Dec 31, 2021 | $275.21M | -15.3% |
| Q3 FY2021 | Sep 30, 2021 | $282.19M | -12.6% |
| Q2 FY2021 | Jun 30, 2021 | $289.32M | +2.5% |
| Q1 FY2021 | Mar 31, 2021 | $305.20M | +5.2% |
| Q4 FY2020 | Dec 31, 2020 | $324.76M | +22.6% |
| Q3 FY2020 | Sep 30, 2020 | $322.98M | +19.9% |
| Q2 FY2020 | Jun 30, 2020 | $282.35M | -0.5% |
| Q1 FY2020 | Mar 31, 2020 | $290.22M | -0.4% |
| Q4 FY2019 | Dec 31, 2019 | $264.81M | -12.8% |
| Q3 FY2019 | Sep 30, 2019 | $269.39M | +6.8% |
| Q2 FY2019 | Jun 30, 2019 | $283.79M | +9.5% |
| Q1 FY2019 | Mar 31, 2019 | $291.45M | +8.1% |
| Q4 FY2018 | Dec 31, 2018 | $303.65M | +5.7% |
| Q3 FY2018 | Sep 30, 2018 | $252.29M | -13.6% |
| Q2 FY2018 | Jun 30, 2018 | $259.10M | -7.0% |
| Q1 FY2018 | Mar 31, 2018 | $269.70M | -7.8% |
| Q4 FY2017 | Dec 31, 2017 | $287.35M | -6.2% |
| Q3 FY2017 | Sep 30, 2017 | $292.00M | -8.9% |
| Q2 FY2017 | Jun 30, 2017 | $278.71M | – |
| Q1 FY2017 | Mar 31, 2017 | $292.47M | – |
| Q4 FY2016 | Dec 31, 2016 | $306.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $320.42M | – |
See a number that looks wrong?